Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta2-agonist tocolysis for preterm labor by Landau Ruth, Morales Michel A, Antonarakis Stylianos E, Blouin Jean-Louis, Smiley Richard M in Clinical pharmacology and therapeutics (2005).

[PMID: 16338281] PubMed


Beta(2)-adrenergic receptor (beta(2)AR) agonists are not consistently successful when administered as tocolytic therapy. The beta(2)AR displays genetic variability; an arginine-to-glycine substitution at codon 16 (Arg16Gly) has been shown to increase receptor desensitization in response to agonist exposure, whereas a substitution of glutamate for glutamine at codon 27 (Gln27Glu) decreases down-regulation. We have demonstrated that homozygosity for Arg16 protects against preterm delivery. Our goal was to determine whether beta(2)-agonists are more effective in women with the Arg16 genotype and preterm labor.

[ hide abstract ]

Discussed In Paper


Dosing Information

No dosing information annotated.